TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06059131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KeenMind
Description: 320 mg/d (2 capsules/d) during 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 320 mg/d (2 capsules/d) during 3 months
Study: NCT05940454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected
Study: NCT06257602

Intervention type: PROCEDURE
Intervention: Tragal graft tympanoplasty
Description: Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft

Intervention type: PROCEDURE
Intervention: Tragal graft tympanoplasty
Description: Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
Study: NCT04409639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
Study: NCT06069440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming Fatigue Task
Description: Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
Study: NCT06068426

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound Shear wave elastography
Description: TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
Study: NCT04644315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
Study: NCT04994470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-week web-based self-help intervention based on principles of positive psychology
Description: The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Two-week web-based text messages containing fun facts
Description: The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2).
Study: NCT06102018

Intervention type: DIAGNOSTIC_TEST
Intervention: Collect blood and urine，pathological specimens if necessary
Description: Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube

Intervention type: DIAGNOSTIC_TEST
Intervention: Collect blood and urine，pathological specimens if necessary
Description: Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube

Intervention type: DIAGNOSTIC_TEST
Intervention: Collect blood and urine，pathological specimens if necessary
Description: Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
Study: NCT05416554

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
Study: NCT06034990

Intervention type: OTHER
Intervention: 10-min online survey
Description: This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
Study: NCT05782634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate satellite implant with immediate loading
Description: Infiltration anesthesia will be administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 . Injection to control pain and bleeding for hemostasis.~Dental extraction will be done with minimal force to avoid trauma to the bone. Flab will be released, different drilling sizes will be used to attain the final drill size of the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, a satellite implant device is attached to the implant's abutment placed on the buccal and palatal plates of bone and retention between the abutment and microplate will help in neglecting the lateral destructive forces . sutures will be done . Impression will be taken for immediate loading with the final crown. Cone beam will be done.
Study: NCT04769648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-ocular™ Topical Gel 1%
Description: Pro-ocular™ is a topical gel applied dermally to forehead twice-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
Study: NCT06147024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: historical control
Description: Received a conventional preoperative assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed lesion model
Description: Received 3D printed lesion models for preoperative planning
Study: NCT06432738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82
Description: This group of subjects take ZL-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82
Description: This group of subjects take ZL-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82
Description: This group of subjects take ZL-82

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-82
Description: This group of subjects take ZL-82

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZL-82 placebo
Description: This group of subjects take ZL-82 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZL-82 placebo
Description: This group of subjects take ZL-82 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZL-82 placebo
Description: This group of subjects take ZL-82 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZL-82 placebo
Description: This group of subjects take ZL-82 placebo
Study: NCT05619965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedative
Description: dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sedative
Description: dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Awake endotracheal intubation by Glidescope videolaryngoscope
Description: Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Awake endotracheal intubation by Fiberoptic bronchoscope
Description: Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
Study: NCT04852640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation Program (ARP)
Description: The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonspecific Passive Intervention (NPI)
Description: The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
Study: NCT05374473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Content in the intervention arm was adapted from an evidence-based lifestyle modification program for people with MS outlined in print previously presented in a face-to-face format. The integrated lifestyle modification program translates the research evidence regarding modification of lifestyle related risk factors and health outcomes based on a detailed review of the literature around modifiable lifestyle risk factors that may influence MS disease progression, as outlined in the book Overcoming Multiple Sclerosis: the 7-step recovery program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard-care
Description: Content in standard-care arm was adapted from MS-related websites
Study: NCT05331911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
Study: NCT05767567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Check Your Drinking (CYD)
Description: The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
Study: NCT05681559

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medi for All
Description: Please see description of Medi for All arm

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fiber Supplementation
Description: Please see description of Fiber Supplementation arm
Study: NCT05331911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
Study: NCT05974462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 MG
Description: 125 mg daily for 3 days diluted in saline solution 250 mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV saline solution 0.9%
Description: Saline solution 0.9% 250 mL
Study: NCT04954248

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected radiotracer with PET Insert
Description: 1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected radiotracer with PET Insert
Description: 1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.
Study: NCT06492655

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-383(Fed)
Description: After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-383(Fed)
Description: After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-383(Fasted)
Description: After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-383(Fasted)
Description: After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
Study: NCT06097390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration
Study: NCT06260514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-1051
Description: WEE1 Inhibitor
Study: NCT05967039

Intervention type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy in respiratory rehabilitation

Intervention type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy in respiratory rehabilitation
Study: NCT05495048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOSES VIIIA
Description: totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery with mini-laparotomy
Description: laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
Study: NCT04856592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Vici® Venous Stent System
Description: The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)
Description: The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
Study: NCT05536128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
Study: NCT06199466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given by IV
Study: NCT05753579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Mobilization
Description: Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization Exercise
Description: Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilization Exercise
Description: Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
Study: NCT06199466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-13027
Description: Given by PO
Study: NCT05377697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry lavender flower scent
Description: Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
Study: NCT06506487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doll Therapy
Description: Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers.
Study: NCT05028621

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
Study: NCT04026984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV-MMX
Description: 2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablets
Study: NCT05311384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keys Constraint-induced Movement Therapy protocol
Description: All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
Study: NCT05657184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGEND001
Description: Transplantation of REGEND001 for dose escalation.
Study: NCT04786184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM Breathing
Description: CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional outpatient PR
Description: After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information.
Study: NCT05668780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx Coaching
Description: The intervention will consist of:~1. a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD~2. rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD~3. training for primary care providers
Study: NCT05436873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Description: MRI guided High Intensity Focused Ultrasound sonication.